
Oncolines publishes with Elevar Therapeutics on selective VEGFR2 inhibitor rivoceranib
Vascular endothelial growth factor receptor 2 (VEGFR2) is a key regulator of tumor angiogenesis, the formation of new blood vessels from existing vasculature. VEGFR2 has been an attractive target for anti-cancer therapy. The study highlights the power of combining Oncolines’ ResidenceTimer platform and Carna Bioscience’s kinase activity profiling.